Jianqiang Li, Ph.D.

Scientific Founder, CSO, Director of the Board

Jianqiang Li has over 20 years of academic and industry experience in immunology and cell therapy. Dr. Li has published 13 papers in top-ranked journals, including Nature Medicine, Blood, and the Journal of Immunology, with a cumulative impact index over 60. Dr. Li is an invited speaker at ASH, ASBMT, ICBS, ECI and Gamma-Delta T Cell International Conference.

Dr. Li independently set up an efficient CAR-T production system, achieved major breakthroughs in the development and clinical application of allogeneic CAR-γδ T-cell therapy, and made important contributions to the antigen presentation and activation mechanism of Vγ9Vδ2 T-cells. He has successfully developed CAR-γδ T-cell products derived from human cord blood.

  • Master of Immunology, Institute of Basic Medicine, Peking Union Medical College (2003-2006)
  • Doctor of Immunology, University of Würzburg (2006-2009)
  • Postdoctoral Fellow, City of Hope National Medical Center (2010)
  • Senior Scientist, R&D Department at Fred Hutchinson Cancer Research Center (2011-2016)

Shengmin Guo 

Co-founder, CEO, Director of the Board

Shengmin Guo has over 20 years of experience in the pharmaceutical industry. Previously, Ms. Guo worked at CSPC NBP Pharmaceutical Co. Ltd (HKEX: 01093), accumulating 12 years of marketing and management experience as Marketing Director, Deputy Manager and Vice President, and 10 years as Senior Manager of Human Resources.

Ms. Guo led the development and commercialization of a novel drug launch, with peak annual sales of 3 Billion RMB.